Integral Biomarkers in Clinical Trial Design and Conduct Wednesday, July 20, 2022 The CCTG New Investigator Clinical Trials Course is fast approaching and has already reached the maximum registration. The course will be held August 3 – 5, 2022 in Kingston, Ontario to provide and facilitate investigator education and training designed to educate new investigators from across the country about the essentials of clinical trial conduct in the Canadian research environment. The organizing team is happy to announce that Dr. Alexander Wyatt will be the keynote speaker addressing the course participants on The Integral Biomarkers in Clinical Trial Design and Conduct: The Experience of CCTG IND234 About Dr. Wyatt Dr. Wyatt’s is the Correlative Sciences Committee Chair for the CCTG GU disease site committee and his research is focused on metastatic genitourinary cancers, including prostate and bladder cancer. To enable genomic profiling of these cancers, his team has pioneered methods for circulating tumour DNA analysis of prostate cancer from minimally invasive blood samples, developed targeted sequencing approaches, built custom bioinformatic software and amassed important clinical data from men with metastatic prostate cancer, enabling comparison of genomic alterations with treatment outcomes. He leads the DNA research for the IND234 clinical trial which, uses liquid biopsy technology to screen for genomic markers in prostate cancer patients. B.Sc. (Biology), University of Nottingham D.Phil. (Physiology, Anatomy and Genetics), University of Oxford Senior Research Scientist, Vancouver Prostate Centre Scientist, Michael Smith Genome Sciences Centre, BC Cancer Assistant Professor, Department of Urologic Sciences, University of British Columbia For further information on the upcoming NICTC please contact the CCTG Meetings Team: meetings@ctg.queensu.ca
